Previous 10 | Next 10 |
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia PR Newswire Curis to review results during conference call, featuring commentary by Dr. Eric Winer , M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET ...
Curis, Inc. (CRIS) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Craig West – Vice President-Investor Relations and Corporate Communications Jim Dentzer – President and Chief Executive Officer Diantha Duvall ...
Curis press release ( NASDAQ: CRIS ): Q3 GAAP EPS of -$0.14 beats by $0.03 . Revenue of $2.83M (-6.9% Y/Y) misses by $0.33M . For further details see: Curis GAAP EPS of -$0.14 beats by $0.03, revenue of $2.83M misses by $0.33M
Curis Provides Third Quarter 2022 Business Update PR Newswire Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022 Curis focuses its resources to drive the development of emavusertib Cash runway exte...
Curis Announces Three Presentations at SITC 2022 PR Newswire LEXINGTON, Mass. , Nov. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today annou...
Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022 PR Newswire LEXINGTON, Mass. , Nov. 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative the...
Summary A look at a couple of drugs in Curis pipeline that could generate some big returns if they are able to gain approval from the FDA. The company should have enough capital to fund operations through 2024. The FDA has lifted its partial hold on the TakeAim Leukemia and Ta...
Curis Announces Date for the 1st Symposium on IRAK4 in Cancer PR Newswire Symposium hosted by Guillermo Garcia-Manero , M.D.; Hagop Kantarjian , M.D.; Amit Verma , M.B.B.S. Academics and industry professionals will gather virtually on October 7, 2...
Curis Announces Date for the 2nd Annual VISTA Symposium PR Newswire Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle , Ph.D. LEXINGTON, Mass. , Sept. 19, 2022...
The following slide deck was published by Curis, Inc. in conjunction with this event. For further details see: Curis (CRIS) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...